These mutations correlate with decreased overall survival, but sensitize the respective CTCL cells towards MEK-inhibition-induced apoptosis which represents a promising novel therapeutic target in CTCL. This evidence concerns the gene MAP2K7 and primary cutaneous T-cell non-Hodgkin lymphoma.